Tema ETFs LLC Acquires 3,134 Shares of Johnson & Johnson $JNJ

Posted by Brenda Bartman on Aug 12th, 2026

Tema ETFs LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 4.4% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 73,885 shares of the company’s stock after acquiring an additional 3,134 shares during the quarter. Tema ETFs LLC’s holdings in Johnson & Johnson were worth $18,765,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. World Investment Advisors raised its stake in Johnson & Johnson by 19.6% during the 4th quarter. World Investment Advisors now owns 161,343 shares of the company’s stock valued at $33,390,000 after buying an additional 26,450 shares during the last quarter. Benchmark Financial LLC purchased a new position in shares of Johnson & Johnson in the 4th quarter worth $554,000. Principal Financial Group Inc. boosted its stake in shares of Johnson & Johnson by 0.8% in the 4th quarter. Principal Financial Group Inc. now owns 3,410,177 shares of the company’s stock worth $705,736,000 after buying an additional 28,370 shares during the last quarter. KBC Group NV grew its holdings in shares of Johnson & Johnson by 21.8% in the fourth quarter. KBC Group NV now owns 2,296,831 shares of the company’s stock worth $475,330,000 after acquiring an additional 410,720 shares during the period. Finally, SageGuard Financial Group LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at $1,019,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,779,963.81. This trade represents a 50.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 48,972 shares of company stock valued at $12,295,205 in the last 90 days. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of a number of recent research reports. Weiss Ratings upgraded Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, July 24th. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Sanford C. Bernstein boosted their target price on shares of Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a research report on Wednesday, April 15th. HSBC set a $290.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Monday, July 6th. Finally, Barclays boosted their price target on Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a report on Wednesday, April 15th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $268.22.

Get Our Latest Research Report on Johnson & Johnson

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Johnson & Johnson’s fiscal second-quarter results exceeded expectations, with revenue rising 6.6% year over year to $25.31 billion and adjusted earnings per share reaching $2.90. The company also raised or reaffirmed its full-year outlook, reinforcing confidence in operating momentum. Johnson & Johnson vs. Medtronic
Positive Sentiment: The FDA granted De Novo authorization for J&J’s OTTAVA soft-tissue robotic surgery system, giving its MedTech business an entry point into a growing market and potentially creating a new source of long-term growth. OTTAVA FDA approval
Positive Sentiment: Additional growth initiatives include a preferred cardiac electrophysiology technology agreement with ACCESS for ambulatory surgery centers, a priority review for RYBREVANT FASPRO, and a collaboration focused on in vivo CAR-T therapies. ACCESS strategic agreement
Neutral Sentiment: Analysts and commentators generally view JNJ as a hold or moderate buy. Shares are trading above their 50-day and 200-day moving averages, but the stock’s strong rally leaves less valuation support; investors are weighing its roughly 30 times earnings multiple against future growth. JNJ nearing its 52-week high
Negative Sentiment: Patent expirations, MedTech competition, pipeline execution risks and ongoing talc litigation remain important overhangs. J&J’s proposed $5.5 billion talc settlement framework could reduce legal uncertainty, but it also highlights the potential for substantial cash costs and continued investor scrutiny. OTTAVA FDA win and talc deal

Johnson & Johnson Trading Down 1.0%

JNJ stock opened at $259.28 on Wednesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. Johnson & Johnson has a 1-year low of $171.81 and a 1-year high of $274.90. The business has a 50 day simple moving average of $249.94 and a two-hundred day simple moving average of $240.47. The company has a market capitalization of $624.84 billion, a price-to-earnings ratio of 30.04, a PEG ratio of 2.50 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. During the same quarter last year, the business posted $2.77 earnings per share. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Research analysts anticipate that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s payout ratio is presently 62.11%.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.